USANA Health Sciences, Inc. announced Kevin Guest will return to lead the company as CEO, effective immediately. The leadership transition is part of USANA’s larger strategy to accelerate growth and enhance shareholder value. Over three decades with the company, Guest has served in a number of roles, including leading as CEO from 2015-2023.

Guest will continue to serve in his role as Chairman and succeeds Jim Brown, who will now step down from his role as CEO and President.

“We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over the past 3 years,” said Gilbert Fuller, lead independent director of the USANA Board of Directors. “As USANA enters its next phase, the board believes this transition will position the company to accelerate strategic priorities that meaningfully contribute to long-term growth opportunities. Kevin has the full support of the board and the company’s senior leadership team. He also has good relationships with the company’s sales force and brings a combination of deep sales, organizational and strategic experience.”

USANA stated that Guest’s demonstrated ability to “build high‑performing teams, navigate complex industry dynamics and maintain a clear strategic vision earned the confidence of the board and the broader USANA community.” During his tenure as CEO, Guest led the company through a period of “meaningful global expansion” and strengthened its operational performance, leading to record results and a strong presence in key international markets.

“I am truly energized to return to the company and lead this exceptional organization once again,” Guest said. “I know firsthand the strength of our sales force and management team, the resilience of our culture, the differentiation of our science-based products and the meaningful opportunities ahead. I’m grateful to the board for their confidence, and I look forward to working closely with our team to drive the next chapter of sustainable growth.”